Fig. 5. The TAM-67 dominant-negative c-jun construct inhibits PRRIV activity. (A) EL4 cells were transfected with 10 µg of the PRRIVWT construct together with different amounts of pCMV-TAM67. (B) EL4 cells were transfected with 10 µg of WT-PRRIVWT construct together with different amounts of pCMV-TAM67. (C) EL4 cells were transfected with 10 µg of WT-PRRIVm3 construct, which has mutant AP-1 sites in PRRIV, together with different amounts of pCMV-TAM67. In (A–C), transfected cells were either not stimulated or stimulated with PI.